Decreased Levels of PSD95 and Two Associated Proteins and Increased Levels of BCl2 and Caspase 3 in Hippocampus from Subjects with Amnestic Mild Cognitive Impairment: Insights into Their Potential Roles for Loss of Synapses and Memory, Accumulation of Aβ, and Neurodegeneration in a Prodromal Stage of Alzheimer’s Disease

Rukhsana Sultana, 1 William A. Banks, 2,3 and D. Allan Butterfield 1*

1 University of Kentucky, Lexington, Kentucky
2 Geriatric Research Education and Clinical Center (GRECC), VA Medical Center, St. Louis, Missouri
3 Department of Internal Medicine, Division of Geriatric Medicine, St. Louis University School of Medicine, St. Louis, Missouri

Alzheimer’s disease (AD) is the most common form of dementia and is pathologically characterized by senile plaques, neurofibrillary tangles, synaptic disruption and loss, and progressive neuronal deficits. The exact mechanism(s) of AD pathogenesis largely remain unknown. With advances in technology diagnosis of a pre-AD stage referred to as amnestic mild cognitive impairment (MCI) has become possible. Amnestic MCI is characterized clinically by memory deficit, but normal activities of daily living and no dementia. In the present study, compared to controls, we observed in hippocampus from subjects with MCI a significantly decreased level of PSD95, a key synaptic protein, and also decreased levels of two proteins associated with PSD95, the N-methyl-D-aspartate receptor, subunit 2A (NR2A) and the low-density lipoprotein receptor-1 (LRP1). PSD95 and NR2A are involved in long-term potentiation, a key component of memory formation, and LRP1 is involved in efflux of amyloid beta-peptide (1-42). Aβ (1-42) conceivably is critical to the pathogenesis of MCI and AD, including the oxidative stress under which brain in both conditions exist. The data obtained from the current study suggest a possible involvement of these proteins in synaptic alterations, apoptosis and consequent decrements in learning and memory associated with the progression of MCI to AD. © 2009 Wiley-Liss, Inc.

Key words: Alzheimer’s disease; mild cognitive impairment; hippocampus; post synaptic density protein 95 (PSD95); low density lipoprotein receptor (LRP1); N-methyl D-aspartate receptor-2A (NR2A)

This research was supported in part by NIH grants to D.A.B [AG-029839; AG-05119, AG-10836] and to W.A.B. [AG-029839].

Contract grant sponsor: NIH (to D.A.B.); Contract grant number: AG-029839; Contract grant number: AG-05119; Contract grant number: AG-10836; Contract grant sponsor: NIH (to W.A.B.); Contract grant number: AG-029839.

*Correspondence to: D. Allan Butterfield, Department of Chemistry, Center of Membrane Sciences, and Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky. E-mail: dabcn@uky.edu
Received 3 March 2009; Revised 16 June 2009; Accepted 7 July 2009
Published online 22 September 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jnr.22227

© 2009 Wiley-Liss, Inc.
of which conceivably can provide insights into progression of MCI to AD.

MCI individuals are broadly grouped into 2 subtypes referred to as: amnestic (memory-affecting) MCI or non-amnestic MCI (no change in memory) (Petersen 2004; Portet et al., 2005). Pathologically, MCI brain shows mild degradation of the hippocampus, sulci, and gyri using magnetic resonance imaging technology (Jack et al., 1999; Fleisher et al., 2008). The rate of amnestic MCI conversion to AD is roughly 10-15% per year; however, in some cases MCI individuals can revert to normal (Petersen 2000).

Brain from subjects with MCI, like AD, contains pathological hallmarks of AD, including SP and NFT and also like AD, has elevated indices of oxidative stress (Keller et al., 2005; Butterfield et al., 2006c; 2007a; 2007b; Small et al., 2006). The main component of SP is amyloid beta-peptide (1-42) [Aβ (1-42)]. Under both in vitro and in vivo conditions Aβ (1-42) is known to cause increased oxidative stress (Yatin et al., 1999; Boyd-Kimball et al., 2005; Opip et al., 2008). This observation is consistent with the notion that Aβ (1-42) plays a causal role in the development and progression of AD (Selkoe 2000). Further, a number of studies suggest that the small oligomers of Aβ are the actual toxic species of this peptide (Aksenov et al., 2001; Lambert et al., 2001; Drake et al., 2003; Murphy et al., 2007). Many MCI patients showed low levels of Aβ in cerebrospinal fluid, in contrast to increased levels of Aβ deposits in the brain (Andreasen et al., 1999; Andreasen and Blennow 2005), suggesting a diminished clearance mechanism of Aβ from brain. Current research identified a number of proteins that could be potentially involved in the efflux of Aβ from brain, including low-density lipoprotein-related-receptor-1 (LRP1) (Ito et al., 2007; Jaeger and Pietrzik 2008), a protein that is investigated in this current study.

Recent reports have shown that protein synthesis in MCI brain may also be decreased in response to oxidative damage to mRNA, which could lead to decreased levels of important proteins that could be involved in the progression of disease (Ding et al., 2005; Cenini et al., 2007; Sultana et al., 2008). Hence, in hippocampus obtained from MCI and control subjects at a short postmortem interval, we tested the hypothesis that levels of PSD95, a key synaptic protein, and two additional proteins associated with PSD95, NR2A and LRP1, had decreased levels. In addition, we tested the hypothesis that hippocampal levels of Bcl2 and Caspase-3 were elevated. PSD95 and NR2A are involved in learning and memory via Ca2+ influx into neurons and as noted above LRP1 is involved with clearance from brain of Aβ (1-42). The data obtained from the current study suggest a possible involvement of these proteins in this prodromal stage of AD.

**MATERIALS AND METHODS**

All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) with exceptions of nitrocellulose membranes (Bio-Rad, Hercules, CA), electrophoretic transfer system (Trans-blot Semi-dry Transfer Cell; Bio-Rad).

**Control and MCI brains**

The Rapid Autopsy Program of the University of Kentucky Alzheimer’s Disease clinical (UK ADC) provided frozen hippocampus samples from six each of MCI and age-matched controls for the present study. All subjects came from the longitudinally followed normal control group that had annual neuropsychological testing and neurological and physical examinations every 2 years. Control subjects had no cognitive complaints, normal cognitive test scores, especially objective memory test scores, and normal neurological examinations. Patients with amnestic MCI met the criteria described by Petersen (Petersen, 2004), which include the following: A memory complaint corroborated by an informant; objective memory test impairment (age and education adjusted); general normal global intellectual function; Clinical Dementia Rating score of 0.0-0.5 (no dementia); and a clinical evaluation that revealed no other cause for memory decline. The postmortem intervals of the samples used in the present study were extremely short, i.e., 2.9 ± 0.5 hr for controls and 3.1 ± 0.4 hr for MCI (Table I).

**Sample Preparation**

The brain tissues (hippocampus) from control or MCI subjects were homogenized in a lysis buffer (10 mM HEPES, 137 mM NaCl, 4.6 mM KCl, 1.1 mM KH2PO4, 0.6 mM MgSO4) containing the protease inhibitors [leupeptin (0.5 mg/mL), pepstatin (0.7 mg/mL), trypsin inhibitor (0.5 mg/mL), and PMSF (40 mg/mL)]. Homogenates were centrifuged at 15,800 × g for 10 min to remove debris. The supernatant was used to determine the total protein concentration by the BCA method (Pierce, Rockford, IL).

**Western Blot Analysis**

For Western blot analysis, 50 µg of hippocampus brain sample from controls and MCI were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by transfer of the proteins to nitrocellulose membranes at 160 mA/gel for 2 hr. The nitrocellulose membranes were blocked for 1 hr at room temperature in fresh blocking
buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.05% Tween 20, pH 7.4, containing 5% BSA). This procedure was then followed by incubation of the membrane with primary antibodies against anti-PSD95 [1:1000] (Cell signaling, Danvers, MA), anti-LRP1 [1:1000] (Santa Cruz Biotech, CA), anti-NR2A [1:1000] (Sigma-Aldrich, St. Louis, MO), anti-BCl2 [1:1000] (Calbiochem, NJ), or anti-caspase-3 [1:1000] Calbiochem, NJ) prepared fresh in wash blot (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.05% Tween 20, pH 7.4) with 3% BSA. Following three washes with wash blot, the blots were incubated with secondary antibody conjugated with horse radish peroxidase in wash blot for 1 hr at room temperature. The blots were washed again three times in wash blot, and the bands were visualized by enhanced chemiluminescence (ECL; Amersham, Life Sciences Inc.).

**Image Analysis**

After immunodetection of proteins of interest, the membranes were completely dried at room temperature and were then scanned using a Microtek Scanmaker 4900 scanner. Images were saved as tiff files and the intensity of the proteins were quantified using scion image analysis software.

**Statistical analysis**

The results are presented as means ± SD. Statistical evaluation was performed using a Student’s t-test. Differences were considered to be significant at p < 0.05.

**RESULTS**

Loss of synapses is one of the key pathological hallmarks of AD. In the current study, we measured the protein levels of some key synaptic proteins in the hippocampal region from subjects with MCI and from age-matched controls. Western blot analyses of hippocampal samples probed with anti-PSD95 showed a significant (p < 0.05) decrease in the levels of this protein in MCI hippocampus compared to the age-matched controls. The PSD 95 blot was stripped with stripping buffer (Sigma-Aldrich, St. Louis, MO) and probed with anti-actin antibody (1:1000) as a loading control (Figure 1C). No significant difference in actin levels was observed between the control and MCI hippocampus. Further, we also measured the levels of post synaptic associated proteins, i.e., NR2A and LRP-1, using anti-NR2A or anti-LRP-1 antibodies, respectively, and both these proteins showed significant decreased levels (p < 0.05) in MCI brain compared to control brain (Fig 2 and Fig 3, respectively).

**DISCUSSION**

In the present study we measured the protein levels of PSD95, NR2A, LRP-1, caspase-3, and Bcl2 in MCI and control hippocampus mainly for two reasons: First, hippocampus is one of the regions of the brain that is involved in learning and memory and is known to be significantly involved in AD and amnestic MCI; second, these proteins are directly or indirectly involved in learning and memory processes, which are severely affected in amnestic MCI and AD. Synaptic communications are important in the process of learning and memory; however, in AD there is clear evidence of loss of synaptic connections in the neocortex and hippocampus, and this loss strongly correlated with the cognitive
decline observed in AD patients (Masliah et al., 1994; Scheff and Price 2003). PSD95, NR2A, and LRP1 proteins are localized at synapses, and the maintenance of the levels of these proteins is important for structure and function of brain cells (Niethammer et al., 1996; Martin et al., 2008). PSD95 is a neuronal scaffolding protein that contains several domains, including three PDZ/DHR (PSD-95, Dlg, ZO-1/Dlg-homologous region) domains, an SH3 (Src-homology-3) domain and a guanylate kinase (GK)-homology domain. PSD95 domains participate in protein–protein interactions; for example, among other proteins, these PSD95 domains are reported to bind to the C-terminus of NR2 subunits (Niethammer et al., 1996) and LRP1 protein (Martin et al., 2008). Hence, PSD95 is important in regulating the functions of other proteins. In the present study, we observed a significant decrease in the level of PSD95 in MCI hippocampus compared to that of control. These results are consistent with the two previous reports of decreased levels of PSD95 in AD brain (Gylys et al., 2004; Love et al., 2006). In contrast, recently another group reported an increased level of PSD95 in AD (Leuba et al., 2008).

In vivo studies in mice reported decreased PSD95 levels could lead to learning and memory impairments, in addition to locomotive impairment (Migaud et al., 2008).
A previous study showed that mice with a mutated form of PSD95, lacking the last PDZ domain, had impaired learning and LTP (Migaud et al., 1998; Mattar et al., 2005). Learning and memory impairment reported previously can be explained based on the alterations in synaptic signaling possibly through NMDA receptors or through interaction with dopamine receptors or perhaps by altering the interplay of glutamatergic and dopaminergic axons on postsynaptic dendritic spines. NMDA receptors and PSD-95 co-cluster in cotransfected cells (Kim et al., 1996). Furthermore, PSD95 and NMDA receptors were reported to be co-localized in primary neurons (Kornau et al., 1995). The molecules involved in regulation of the receptor function appear to be recruited to the proximity of the receptor at synapses by PSD95 (Shiraishi et al., 2003).

### Table II. PSD95, NR2A, LRP-1, BCl2 and Caspase-3 Protein Levels Obtained from Both Control and MCI Hippocampus are Shown as Percent Control (The Latter Taken to be 100%)

<table>
<thead>
<tr>
<th>Proteins</th>
<th>Controls (Mean ± S.D)</th>
<th>MCI (Mean ± S.D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSD95</td>
<td>100 ± 21.3</td>
<td>69.55 ± 19.2</td>
</tr>
<tr>
<td>NR2A</td>
<td>100 ± 19.3</td>
<td>64.9 ± 24.1</td>
</tr>
<tr>
<td>LRP1</td>
<td>100 ± 31.5</td>
<td>66.2 ± 25.0</td>
</tr>
<tr>
<td>BCl2</td>
<td>100 ± 10.3</td>
<td>155 ± 33.1</td>
</tr>
<tr>
<td>Caspase-3</td>
<td>100 ± 21.7</td>
<td>145 ± 24.2</td>
</tr>
</tbody>
</table>
In the present study, we also found that the levels of NR2A are decreased in amnestic MCI hippocampus compared to that of control. As mentioned previously, PSD95 interacts with the NR2A subunit of the NMDA receptor, a heteromeric complex that is composed of the NR1 subunit combined with various types of NR2 subunits, e.g., NR2A, NR2B, NR2C, and NR2D. Consistent with the interaction of PSD95 with NR2A, an in vitro study in fibroblasts showed that PSD-95 may be required for the localization of NMDA receptors to synapses (Buller and Monaghan 1997; Hoe et al., 2006).

The decreased levels of NR2A protein together with decreased levels of PSD95 could possibly make the NMDA receptor less functional with consequent reduced LTP associated with the NMDA receptors. Previous studies showed conflicting results regarding the levels of these various NMDA receptors in AD brain, and the binding sites for NMDA receptors have been shown to be either reduced or stable (Scheuer et al., 1996; Sze et al., 2001; Mishizen-Eberz et al., 2004). The mRNA levels are decreased in the AD brain (Hynd et al., 2003). One study showed reduction of NR1/NR2B receptor expression levels with the progression of AD (Mishizen-Eberz et al., 2004). An in vivo study showed reduced number of cell surface NMDA receptors in mice carrying the familial Swedish APP mutation, suggesting the involvement of Aβ (Snyder et al., 2005). Based on the above-mentioned reasons, we are tempted to speculate that the decreased levels of NR2A found in brain of subjects with amnestic MCI in the current study could be due to reduced levels of PSD95. This suggestion could result in keeping NR2A at the cell surface, which could lead to activation of the NMDA channel, with consequent elevated intracellular Ca$^{2+}$ and increased oxidative stress and excitotoxicity. Other explanations for lower levels of NR2A in MCI brain could include truncation of the C-terminus of NR2A with consequent lack of recognition of this subunit by the anti-NR2A antibody (Sultana and Babu, 2003). Some findings demonstrate reduce synaptic plasticity and glutamatergic transmission is associated with the non-toxic amounts of secreted Aβ peptide. However, the exact role of NMDA receptor activation in AD pathogenesis is still not fully elucidated.

Low-density lipoprotein receptor-related protein 1 (LRP1) is a large, endocytic receptor that mediates the cellular uptake of a great variety of ligands, among which are ApoE-containing lipoproteins, lipoprotein lipase, complexes of proteinases–proteinase inhibitors, and hormones and growth factors such as insulin and platelet–derived growth factor (PDGF) (Croy et al., 2004; May et al., 2005; Martin et al., 2008). LRP1 is also involved in phagocytosis and signaling pathways in addition to many other functions that are still to be discovered (Zilberberg et al., 2004). LRP1 is present both on glial and neuronal cells, and an in vitro study suggests involvement of LRP1 in different aspects of neuronal metabolism (May et al., 2004). Further, LRP1 has been shown to interact with amyloid precursor protein (APP) and also is involved in the regulation of proteolytic processing and the production of the Aβ peptide (Goto and Tanzi 2002; Shi et al., 2006). In addition, LRP1 has been reported to be as one of the mechanism(s) of Aβ clearance from brain, and down-regulation of LRP1 has been reported in human AD brain and endothelial cells (Pritchard et al., 2005).

The down regulation of LRP1 in brain of subjects with amnestic MCI reported here could lead to accumulation of Aβ in the brain resulting in increased SP formation and eventually to the progression to AD pathology. Further, the increased levels of Aβ could also increase the degradation of LRP1 by enhancing the proteasome degradation of LRP1. Since LRP1 is involved in APP processing and the clearance of Aβ, decreased levels of LRP1, as observed in MCI brain in the current study compared to the control, suggest that LRP1 may be involved in the development of SP in AD and other secondary consequences (Lovell et al., 2001; Hardy and Selkoe 2002; Butterfield et al., 2006a; Wenk 2006; Aisen 2008). LRP1 and the NMDA receptor have been assumed from immunohistochemical and co-immunoprecipitation experiments to interact at synapses (Martin et al., 2008). Moreover, LRP1 has been found to regulate calcium influx into neurons after stimulation with the glutamate receptor agonist NMDA (Martin et al., 2008). Since LRP1 has been shown to interact with the postsynaptic density protein PSD-95 and NMDA receptor either directly or indirectly, alteration in the levels of all these three proteins may be able to modulate the conductance of Ca$^{2+}$ through NMDA channel. Hence, decreased levels of these proteins observed in the present study could have consequent detrimental physiological and pathological effects in MCI and could be related to synapse and memory loss, Aβ (1-42) accumulation, and neurodegeneration.

Brains from subjects with MCI show morphological changes that are indicative of cell loss; however, to the present the exact mechanism(s) of cell loss is not clear, but a role of oxidative stress and altered levels of calcium homeostasis have been proposed (Mattson et al., 1993; Mattson and Chan, 2001). One of the proteins that is involved in calcium homeostasis is Bcl2, a member of the Bcl family that plays an important role as an anti-apoptotic and cell survival protein. Alterations in the levels of Bcl2 together with NMDA receptors could lead to altered calcium homeostasis and consequently to activation of apoptotic proteins like caspases–3. Previous studies showed an upregulation of Bcl2 protein levels in the hippocampus and entorhinal cortex of AD brains (Satou et al., 1995; Su et al., 1996). Consistent with and confirming our previous finding of the increased levels of Bcl2 in the inferior parietal lobe of subjects with amnestic MCI (Bader Lange et al., 2008), we observed an increased level of Bcl2 in hippocampus of amnestic MCI subjects. Further, we also observed the upregulation of caspase-3 in MCI subjects, suggesting that
apoptosis might be initiated in MCI hippocampus. The upregulation of the Bcl2 conceivably can be considered as a cellular compensatory mechanism to protect against cell loss.

In conclusion, the hippocampus is one of the areas of the brain that was reported previously to show pronounced neuronal and synaptic loss in AD. Our current findings, suggesting decreased levels of PSD95, NR2A, and LRP-1, with elevated levels of caspase-3 and Bcl2 proteins, may reflect or contribute to neuronal and synaptic loss in the MCI hippocampus. Since PSD95 has been reported as an intracellular linker between LRP1 and the NMDA receptor and all of these proteins are localized at synapses, their decreased levels may alter neuronal functions, consequently leading to the synaptic loss and neurodegeneration. Further molecular dissection of these proteins may be helpful in unraveling the mechanism of conversion of MCI to AD, and may help in finding a therapeutic approach to delay or prevent this devastating disease.

ACKNOWLEDGMENTS

The authors thank the UK ADC for providing the brain specimens used for this study. This research was supported in part by NIH grants to D.A.B [AG-029839; AG-05119, AG-10836] and to W.A.B. [AG-029839].

REFERENCES


